Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

NCT04890509 is registered in ClinicalTrials.gov with BerGenBio ASA as lead sponsor.

NCT NCT04890509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04890509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Lead sponsor
BerGenBio ASA
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2020
Completion date
May 25, 2021
Enrollment
115 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19